Condition

Metastatic NSCLC - Non-Small Cell Lung Cancer clinical trials and research

• 6Clinical trials
• 4Countries

Newest Metastatic NSCLC - Non-Small Cell Lung Cancer clinical trials

All recruiting trials (6)

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• XTX501 in people with metastatic NSCLC and advanced solid tumors

  A first-in-human study tests XTX501, a PD-1/masked IL-2 drug, to see if it is safe and tolerable in people with metastatic NSCLC and selected advanced solid tumors.

  Recruiting at 3 sites Phase 1/2 Xilio Development, Inc. · Canton, Ohio and 2 other locations · NCT07688577

• Amivantamab plus single‑agent chemotherapy for advanced non‑small cell lung cancer with EGFR exon 20 insertion in people unable to receive platinum

  This trial will test whether adding amivantamab to a single chemotherapy drug helps people with metastatic non‑small cell lung cancer that has an EGFR exon 20 insertion who cannot get platinum chemotherapy.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, Roma (RM) · NCT07392658

• Large granular lymphocytes in metastatic non-small cell lung cancer treated with nivolumab

  This study will test whether the percentage of large granular lymphocytes in the blood at baseline and after three months can predict response to nivolumab in people with metastatic non-small cell lung cancer receiving it as second-line therapy.

  Recruiting Necmettin Erbakan University · Konya, Meram · NCT07363811

• Magnesium supplementation added to standard chemo-immunotherapy in advanced NSCLC

  This trial tests whether giving magnesium along with standard chemo-immunotherapy helps people with advanced non-small cell lung cancer.

  Recruiting at 9 sites Phase 2/3 Swiss Cancer Institute · Aarau and 8 other locations · NCT07149649

• Reduced-dose carboplatin doublet plus cemiplimab versus cemiplimab alone for older, frail metastatic NSCLC with PD-L1 under 50%

  This will test whether adding lower-dose carboplatin-based doublet chemotherapy to cemiplimab helps people aged 70 and older who are frail and have metastatic NSCLC with PD-L1 under 50% do better than cemiplimab alone.

  Recruiting at 18 sites Phase 2 Swiss Cancer Institute · Fribourg, Villars-sur-Glâne and 17 other locations · NCT07020065

Related topics

Quick answers

How many Metastatic NSCLC - Non-Small Cell Lung Cancer clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in Switzerland (2 trials), United States (2 trials), Italy (1 trial), Turkey (Türkiye) (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2, Phase 2/3: 1, Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →